Intersect ENT (XENT) Tops Q2 EPS by 3c

Go back to Intersect ENT (XENT) Tops Q2 EPS by 3c

Intersect ENT Reports Second Quarter 2015 Results

August 5, 2015 4:01 PM UTC

Revenue Increased 77% Year Over Year to $15.2 Million and Gross Margins Rise to 81%

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2015.

Recent Highlights

Achieved revenue of $15.2 million, an increase of 77% over Q2 2014. Realized gross margin of 81%, versus 73% in Q2 2014. Completed enrollment of the first cohort... More